A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19-Reference-Cited by-同舟云学术

A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19

Published:2020-11-17 Issue:12 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Doi Yohei¹²^ORCID,Hibino Masaya³,Hase Ryota¹⁴,Yamamoto Michiko⁵,Kasamatsu Yu⁶,Hirose Masahiro⁷,Mutoh Yoshikazu⁸^ORCID,Homma Yoshito⁹,Terada Masaki¹⁰,Ogawa Taku¹¹,Kashizaki Fumihiro¹²,Yokoyama Toshihiko¹³,Koba Hayato¹⁴,Kasahara Hideki¹⁵,Yokota Kazuhisa¹⁶,Kato Hideaki¹⁷,Yoshida Junichi¹⁸,Kita Toshiyuki¹⁹,Kato Yasuyuki²⁰,Kamio Tadashi²¹,Kodama Nobuhiro²²,Uchida Yujiro²³,Ikeda Nobuhiro²⁴,Shinoda Masahiro²⁵,Nakagawa Atsushi²⁶,Nakatsumi Hiroki²⁷,Horiguchi Tomoya²⁸,Iwata Mitsunaga³,Matsuyama Akifumi²⁹,Banno Sumi³⁰,Koseki Takenao³⁰³¹,Teramachi Mayumi³⁰,Miyata Masami³⁰,Tajima Shigeru³²,Maeki Takahiro³²,Nakayama Eri³²,Taniguchi Satoshi³²,Lim Chang Kweng³²,Saijo Masayuki³²^ORCID,Imai Takumi³³,Yoshida Hisako³³,Kabata Daijiro³³,Shintani Ayumi³³,Yuzawa Yukio³⁴,Kondo Masashi²⁸³⁰

Affiliation:

1. Departments of Microbiology and Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

2. Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

3. Department of Emergency and General Internal Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

4. Department of Infectious Diseases, Japanese Red Cross Narita Hospital, Narita, Chiba, Japan

5. Department of Respiratory Medicine, Sagamihara Kyodo Hospital, Sagamihara, Kanagawa, Japan

6. Infection Control and Clinical Laboratory, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan

7. Department of Respiratory Medicine, Fujita Health University Bantane Hospital, Nagoya, Aichi, Japan

8. Department of Infectious Diseases, Tosei General Hospital, Seto, Aichi, Japan

9. Department of Respiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Ehime, Japan

10. Department of Respiratory Medicine, Saiseikai Niigata Hospital, Niigata, Niigata, Japan

11. Center for Infectious Diseases, Nara Medical University, Kashihara, Nara, Japan

12. Department of Respiratory Medicine, Isehara Kyodo Hospital, Isehara, Kanagawa, Japan

13. Department of Respiratory Medicine, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Aichi, Japan

14. Department of Respiratory Medicine, Komatsu Municipal Hospital, Komatsu, Ishikawa, Japan

15. Department of Rheumatology, NTT East Sapporo Hospital, Sapporo, Hokkaido, Japan

16. Department of Infectious Diseases, Tokyo Metropolitan Health and Medical Corporation Ebara Hospital, Ohta, Tokyo, Japan

17. Infection Prevention and Control Department, Yokohama City University Hospital, Yokohama, Kanagawa, Japan

18. Department of Chest Surgery, Shimonoseki City Hospital, Shimonoseki, Yamaguchi, Japan

19. Department of Respiratory Medicine, National Hospital Organization Kanazawa Medical Center, Kanazawa, Ishikawa, Japan

20. Department of Infectious Diseases, International University of Health and Welfare Narita Hospital, Narita, Chiba, Japan

21. Department of Intensive Care, Shonan Kamakura General Hospital, Kamakura, Kanagawa, Japan

22. Department of General Internal Medicine, Fukuoka Tokushukai Hospital, Kasuga, Fukuoka, Japan

23. Department of General Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan

24. Department of General Internal Medicine, Eiju General Hospital, Taito, Tokyo, Japan

25. Department of Respiratory Medicine, Tokyo Shinagawa Hospital, Shinagawa, Tokyo, Japan

26. Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan

27. Department of Respiratory Medicine, Ishikawa Prefectural Central Hospital, Kanazawa, Ishikawa, Japan

28. Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

29. Department of Regenerative Medicine and Stem Cell Biology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

30. Center for Clinical Trial and Research Support, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

31. Department of Clinical Pharmacy, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

32. Department of Virology I, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan

33. Department of Medical Statistics, Osaka City University Graduate School of Medicine, Osaka, Osaka, Japan

34. Department of Nephrology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

Abstract

Favipiravir is an oral broad-spectrum inhibitor of viral RNA-dependent RNA polymerase that is approved for treatment of influenza in Japan. We conducted a prospective, randomized, open-label, multicenter trial of favipiravir for the treatment of COVID-19 at 25 hospitals across Japan. Eligible patients were adolescents and adults admitted with COVID-19 who were asymptomatic or mildly ill and had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Patients were randomly assigned at a 1:1 ratio to early or late favipiravir therapy (in the latter case, the same regimen starting on day 6 instead of day 1).

Funder

Japan Agency for Medical Research and Development

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01897-20

Reference12 articles.

1. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

2. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses

3. Favipiravir (T-705), a novel viral RNA polymerase inhibitor